Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.
نویسندگان
چکیده
Asymptomatic antiphospholipid antibody (aPL) carriers with high risk for thrombosis may benefit from preventive anticoagulation. It was our objective to test whether the risk of thrombosis increases with: 1). increasing titres of anticardiolipin antibodies (aCL) after adjustment for other cardiovascular risk factors and 2). the number of aPL detected. In a cross-sectional study, blood was collected from clinics in two teaching hospitals. The study included 208 individuals suspected of having an aPL and 208 age- and sex-matched controls having blood drawn for a complete blood count. Clinical variables included history of previous arterial (ATE) or venous (VTE) thrombotic events, traditional risk factors for cardiovascular disease, and systemic lupus erythematosus (SLE). Laboratory variables included IgG/IgM aCL, lupus anticoagulant, and IgG/IgM anti-beta2-glycoprotein I. Mean age was 46.5 years and 83% were female. Seventy-five of the 416 participants had >or= 1 aPL, and 69 had confirmed >or= 1 ATE or VTE. Family history was positive in 48% of participants, smoking in 28%, hypertension in 16%, diabetes in 6%, and SLE in 20%. A 10-unit increase in aCL IgG titre was associated with an odds ratio (OR) [95% CI] of 1.07 [1.01-1.13] for ATE and 1.06 [1.02-1.11] for VTE. The odds of a previous thrombosis increased with each additional aPL detected: 1.5 [0.93-2.3] for ATE and 1.7 [1.1-2.5] for VTE. These results indicate that increased titres of aCL and multiple aPL were associated with an increased risk of a previous thrombotic event.
منابع مشابه
Prevalence of Antiphospholipid Antibodies in Syrian Patients with Thrombosis
Background: Antiphospholipid antibodies (aPL) are a heterogeneous family of anti-bodies associated with thrombosis and other complications. Objective: To study the prevalence of aPL in patients with thrombosis at Aleppo University Hospitals, Syria. Methods: One hundred and fifty-seven patients with venous and arterial thrombosis and 63 healthy controls were studied. Anticardiolipin antibodies (...
متن کاملComparison of Serum Level of Antiphospholipid Antibodies and Homocysteine in Patients with Pemphigus Vulgaris and Healthy Subjects: A Case-Control Study
Introduction: Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membrane. Antiphospholipid antibodies are a group of autoantibodies found in patients with autoimmune diseases. Due to the risk for thrombotic events in autoimmune diseases, we decided to evaluate the correlation between pemphigus vulgaris and predictive elements of atherothrombosis including antiphospho...
متن کاملProphylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis.
BACKGROUND A high incidence of both arterial and venous thromboembolic events has been reported in patients with systemic lupus erythematosus (SLE), but the risks and benefits of primary prophylactic antithrombotic therapy have not been assessed. We measured the clinical benefit of 3 antithrombotic regimens in patients with SLE without antiphospholipid antibodies, with anticardiolipin antibodie...
متن کاملComparison of Antiphospholipid Antibodies between Preeclamptsia and Normal Pregnant Women
Antiphospholipid antibodies (APLA) may be detected in normal pregnancies and also may cause thrombosis, recurrent fetal loss, placental infarction and preeclampsia. In the present study the possible differences in APLA titer between healthy pregnant women and preeclampsia cases without history of thrombosis was examined. The APLA titer in 50 healthy pregnant women with 50 preeclampsia cases wit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Thrombosis and haemostasis
دوره 90 1 شماره
صفحات -
تاریخ انتشار 2003